Lung cancer with nephrotic syndrome as a paraneoplastic syndrome: A case report

Yu,Xuesong; Fan,Zhiming; Chen,Wei; Wang,Zhe

doi:10.3892/mco.2020.2156

Lung cancer with nephrotic syndrome as a paraneoplastic syndrome: A case report

Authors:
- Xuesong Yu
- Zhiming Fan
- Wei Chen
- Zhe Wang
View Affiliations

Affiliations: Department of Nephrology, The First Naval Hospital of Southern Theater of People's Liberation Army, Zhanjiang, Guangdong 524005, P.R. China, Department of Oncology, The First Naval Hospital of Southern Theater of People's Liberation Army, Zhanjiang, Guangdong 524005, P.R. China, Department of Oncology and Southwest Cancer Center, Southwest Hospital, Military Medical University, Shapingba, Chongqing 400038, P.R. China
Published online on: October 19, 2020 https://doi.org/10.3892/mco.2020.2156
Article Number: 86

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Paraneoplastic syndromes are immune disorders associated with clinical signs and symptoms caused by substances produced by malignant diseases and are not directly associated with a primary or metastatic tumour. The symptoms are the effects of hormones, immune cross‑reactivity or cytokines. Paraneoplastic nephrotic syndrome (PNS) is often associated with membranous nephropathy (MN) in elderly patients with solid tumours, and there is continued debate regarding whether corticosteroids or immunosuppressants should be combined with cancer therapy for the syndrome. The present report describes a male patient with lung cancer associated with secondary MN who achieved remission under radiotherapy, with no use of corticosteroids or immunosuppressants. This case is rare. Therefore, when treating PNS related to lung cancer, more attention should be paid to the treatment of the cancer.

View Figures

View References

1	Takane K, Midorikawa Y, Yamazaki S, Kajiwara T, Yoshida N, Kusumi Y and Takayama T: Gastrointestinal stromal tumor with nephrotic syndrome as a paraneoplastic syndrome: A case report. J Med Case Rep. 8(108)2014.PubMed/NCBI View Article : Google Scholar
2	Zech P, Colon S, Pointet P, Deteix P, Labeeuw M and Leitienne P: The nephrotic syndrome in adults aged over 60: Etiology, evaluation and treatment of 76 cases. Clin Nephrol. 17:232–236. 1982.PubMed/NCBI
3	Galloway J: Remarks on Hodgkin's disease. Br Med J. 2:1201–1208. 1922.PubMed/NCBI View Article : Google Scholar
4	Lee JC, Yamauchi H and Hopper J Jr: The association of cancer and the nephrotic syndrome. Ann Intern Med. 64:41–51. 1966.PubMed/NCBI View Article : Google Scholar
5	Vivarelli M, Emma F, Pellé T, Gerken C, Pedicelli S, Diomedi-Camassei F, Klaus G, Waldegger S, Ronco P and Debiec H: Genetic homogeneity but IgG subclass-dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies. Kidney Int. 87:602–609. 2015.PubMed/NCBI View Article : Google Scholar
6	Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR and Kunis CL: North America Nephrotic Syndrome Study Group. Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial. Kidney Int. 59:1484–1490. 2001.PubMed/NCBI View Article : Google Scholar
7	Beck LH Jr and Salant DJ: Membranous nephropathy: Recent travels and new roads ahead. Kidney Int. 77:765–770. 2010.PubMed/NCBI View Article : Google Scholar
8	Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, Cosio FG, Cattran DC and Salant DJ: Rituximab-induced depletion of Anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol. 22:1543–1550. 2011.PubMed/NCBI View Article : Google Scholar
9	Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, Baltar J, Fernández-Fresnedo G, Martín C, Pons S, et al: Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 21:697–704. 2010.PubMed/NCBI View Article : Google Scholar
10	Ye WL, Tang N, Wen YB, Li H, Li MX, Du B and Li XM: Underlying renal insufficiency: The pivotal risk factor for Pneumocystis jirovecii pneumonia in immunosuppressed patients with non-transplant glomerular disease. Int Urol Nephrol. 48:1863–1871. 2016.PubMed/NCBI View Article : Google Scholar
11	Fujita F, Ishii S, Hirano S, Izumi S, Takeda Y and Kobayashi N: Response of paraneoplastic nephrotic syndrome to corticosteroids combined with chemotherapy for advanced lung cancer: A case report and literature review. Int Canc Conf J. 1:88–92. 2012.
12	Hauber HP: Paraneoplastic syndromes in lung cancer. Pneumologie. 65:347–358. 2011.PubMed/NCBI View Article : Google Scholar
13	Miret M, Horváth-Puhó E, Déruaz-Luyet A, Sørensen HT and Ehrenstein V: Potential paraneoplastic syndromes and selected autoimmune conditions in patients with non-small cell lung cancer and small cell lung cancer: A population-based cohort study. PLoS One. 12(e0181564)2017.PubMed/NCBI View Article : Google Scholar
14	Jensen AD, Münter MW, Bischoff H, Haselmann R, Timke C, Krempien R, Sterzing F, Nill S, Heeger S, Hoess A, et al: Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: The NEAR protocol. BMC Cancer. 6(12)2006.PubMed/NCBI View Article : Google Scholar
15	Huo X, Huo B, Wang H, Wang L, Cao Q, Zheng G, Wang J, Chai S, Zhang Z, Yang K, et al: Implantation of computed tomography-guided Iodine-125 seeds in combination with chemotherapy for the treatment of stage III non-small cell lung cancer. J Contemp Brachytherapy. 9:527–534. 2017.PubMed/NCBI View Article : Google Scholar
16	Martinez-Monge R, Pagola M, Vivas I and López-Picazo JM: CT-guided permanent brachytherapy for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC). Lung Cancer. 61:209–213. 2008.PubMed/NCBI View Article : Google Scholar